Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228095 | 0.93 | MAPK14 (0.59) | MAPK14HSP90AB1 | |
| SCHEMBL5225374 | 0.90 | MAPK14 (0.52) | MAPK14HSP90AB1 | |
| SCHEMBL3282615 | 0.89 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL5224292 | 0.86 | MAPK14 (0.53) | MAPK14HSP90AB1 | |
| SCHEMBL1065104 | 0.85 | HSP90AB1 (0.42) | MAPK14HSP90AB1 | |
| SCHEMBL3279301 | 0.85 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL3300727 | 0.85 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL5224529 | 0.85 | MAPK14 (0.58) | MAPK14HSP90AB1 | |
| SCHEMBL5224614 | 0.85 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL3279044 | 0.85 | MAPK14 (0.45) | MAPK14HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1842851-A2 | Novel compounds | Smithkline Beecham Corporation (US) | 2007-10-10 | — | — | EP | claimed |
| US-7235551-B2 | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-26 | — | — | US | claimed |
| EP-1265900-B1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D|PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2007-05-16 | — | — | EP | claimed |
| US-7700768-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7629462-B2 | Tetrasubstituted pyrimidine compounds as chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090048442-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20070238743-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2007-10-11 | — | — | US | disclosed |
| EP-1842851-A2 | Novel compounds | Smithkline Beecham Corporation (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070167467-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-7235551-B2 | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1265900-B1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D|PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1265900-A4 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030100756-A1 | 1,5- disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | GLAXOSMITHKLINE LLC | 2003-05-29 | — | — | US | disclosed |
| EP-1265900-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SmithKline Beecham Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001064679-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100756-A1 | 1,5- disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | MAPKAPK2, MAPK4, MAP4K2 | MAPK14 42/4885HSP90AB1 329/4885 |
| US-20070167467-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | MAPKAPK2, CREBBP, CNBP | MAPK14 81/4885HSP90AB1 277/4885 |
| US-20070238743-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | MAPKAPK2, CREBBP, CNBP | MAPK14 81/4885HSP90AB1 277/4885 |
| US-20090048442-A1 | Novel compounds | CREBBP, MAPKAPK2, CNBP | MAPK14 33/4885HSP90AB1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.